View clinical trials related to Schizophrenia Prodrome.
Filter by:This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.